Abstract
In recent years, the simple paradigm of adipose tissue as merely a fat store is rapidly evolving into a complex paradigm of this tissue as multipotential secretory organ, partitioned into a few large depots, including visceral and subcutaneous location, and many small depots, associated with a variety of organs in the human body. The major secretory compartment of adipose tissue consists of adipocytes, fibroblasts, and mast cells. These cells, using endocrine, paracrine and autocrine pathways, secrete multiple bioactive molecules, conceptualized as adipokines or adipocytokines. This review examines current information in adipobiology of various diseases besides obesity and related diseases such as type 2 diabetes, metabolic syndrome, and cardiovascular disease. Finally, we emphasize the possibilities for adipokine-targeted pharmacology in adiponectin (Acrp30, apM1, AdipoQ, GBP28), angiotensin II, estrogens, nerve growth factor, tumor necrosis factor-a, and also adipose mast cells.
Keywords: adipobiology, adipokines, adipokine targeted pharmacology, adipose tissue, adiponectin, angiotensin II, adipose mast cells
Current Pharmaceutical Design
Title: Adipobiology of Disease: Adipokines and Adipokine-Targeted Pharmacology
Volume: 9 Issue: 12
Author(s): G. N. Chaldakov, I. S. Stankulov, M. Hristova and P. I. Ghenev
Affiliation:
Keywords: adipobiology, adipokines, adipokine targeted pharmacology, adipose tissue, adiponectin, angiotensin II, adipose mast cells
Abstract: In recent years, the simple paradigm of adipose tissue as merely a fat store is rapidly evolving into a complex paradigm of this tissue as multipotential secretory organ, partitioned into a few large depots, including visceral and subcutaneous location, and many small depots, associated with a variety of organs in the human body. The major secretory compartment of adipose tissue consists of adipocytes, fibroblasts, and mast cells. These cells, using endocrine, paracrine and autocrine pathways, secrete multiple bioactive molecules, conceptualized as adipokines or adipocytokines. This review examines current information in adipobiology of various diseases besides obesity and related diseases such as type 2 diabetes, metabolic syndrome, and cardiovascular disease. Finally, we emphasize the possibilities for adipokine-targeted pharmacology in adiponectin (Acrp30, apM1, AdipoQ, GBP28), angiotensin II, estrogens, nerve growth factor, tumor necrosis factor-a, and also adipose mast cells.
Export Options
About this article
Cite this article as:
Chaldakov N. G., Stankulov S. I., Hristova M. and Ghenev I. P., Adipobiology of Disease: Adipokines and Adipokine-Targeted Pharmacology, Current Pharmaceutical Design 2003; 9 (12) . https://dx.doi.org/10.2174/1381612033455152
DOI https://dx.doi.org/10.2174/1381612033455152 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design subject Index To Volume 1
Current Drug Targets - Infectious Disorders Interactions Between the Sympathetic Nervous System and Angiotensin System in Renovascular Hypertension
Current Hypertension Reviews Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders
Current Pharmaceutical Design Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials Novel Molecular Targets for the Prevention of Fetal Alcohol Syndrome
Recent Patents on CNS Drug Discovery (Discontinued) Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design The Target of Regulating The ATP-binding Cassette A1 Protein (ABCA1): Promoting ABCA1-Mediated Cholesterol Efflux in Different Cells
Current Pharmaceutical Biotechnology Hypertensive Pharmacogenomics in African Americans
Current Pharmacogenomics Manual Thrombectomy During Primary Coronary Intervention in Acute Myocardial Infarction: A Brief Review
Reviews on Recent Clinical Trials L-Arginine Signalling Potential in the Brain: The Peripheral Gets Central
Recent Patents on CNS Drug Discovery (Discontinued) Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Recommendations for the Treatment of Hypertension in Elderly People
Cardiovascular & Hematological Agents in Medicinal Chemistry Renal Cytochrome P450-Derived Eicosanoids and Hypertension
Current Hypertension Reviews Harnessing CD36 to Rein in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Redox Signaling in the Vascular Wall: From Basic Science to Clinical Practice
Current Pharmaceutical Design The Metabolic Syndrome and Chronic Liver Disease
Current Pharmaceutical Design Vesicovaginal Fistula
Current Women`s Health Reviews Mechanisms for Antiplatelet Action of Statins
Current Drug Targets - Cardiovascular & Hematological Disorders